In this HotCopper Capital Compass interview, Race Oncology (ASX:RAC) chairman Dr Pete Smith discusses the company’s “safe and ...

Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...

A new medication found to reduce the chance of the most common types of breast cancer recurring will be available to many ...

Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen ...

Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to ...

A new study details the development of a nanoparticle-based system that delivers concentrated chemotherapy specifically to ...

BerGenBio, reeling from the failure of its lead cancer drug, has opted to merge with fellow Norwegian cancer biotech Oncoinvent.

Multiple myeloma begins when abnormal cells multiply and grow uncontrollably in a person’s bone marrow, crowding out healthy ...

Scientists discovered a cancer-fighting compound in mold from ancient tombs, revealing a powerful new drug against leukemia.

For the first time in Australia, a drug that can delay the growth of tumours is available under the Pharmaceutical Benefits ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...

Royalty Pharma will pay up to $2 billion to Revolution Medicines to support the development and sales of an experimental drug ...